Aptevo Therapeutics Inc
APVO2.639USD
-0.041-1.52%
Market hours （ET）Quotes delayed by 15 min
3.85MMarket Cap
LossP/E TTM
More Details of Aptevo Therapeutics Inc Company
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. It has developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs. Its lead clinical candidates, APVO436 and ALG.APV-527, and preclinical candidates, APVO603 and APVO711, are developed using its ADAPTIR modular protein technology platform. Its preclinical candidate APVO442 is developed using its ADAPTIR-FLEX modular protein technology platform. APVO436 is a bispecific ADAPTIR that is designed to engage CD3 and CD123 to redirect T-cells to destroy leukemia cells expressing the target CD123 molecule on their surface. ALG.APV-527 is a novel investigational bispecific ADAPTIR candidate. APVO603 is a preclinical dual agonist bispecific ADAPTIR candidate designed to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family.
Company Info
Ticker SymbolAPVO
Company nameAptevo Therapeutics Inc
IPO dateJul 20, 2016
CEOMr. Marvin L. White
Number of employees37
Security typeOrdinary Share
Fiscal year-endJul 20
Address2401 4th Ave Ste 1050
CitySEATTLE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code98121-3460
Phone12068380500
Websitehttps://aptevotherapeutics.com/
Ticker SymbolAPVO
IPO dateJul 20, 2016
CEOMr. Marvin L. White
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Marvin L. White
Mr. Marvin L. White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
43.00
+30.30%
Mr. Jeffrey G. Lamothe
Mr. Jeffrey G. Lamothe
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
23.00
+27.78%
Ms. Barbara Lopez Kunz
Ms. Barbara Lopez Kunz
Independent Director
Independent Director
1.00
--
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Director
Independent Director
1.00
--
Dr. John E. Niederhuber, M.D.
Dr. John E. Niederhuber, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.00
--
Ms. So Young Kwon
Ms. So Young Kwon
Senior Vice President, General Counsel, Business Development and Corporate Affairs
Senior Vice President, General Counsel, Business Development and Corporate Affairs
--
--
Ms. Daphne L. Taylor
Ms. Daphne L. Taylor
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Mr. Daniel J. Abdun-Nabi, J.D.
Mr. Daniel J. Abdun-Nabi, J.D.
Independent Director
Independent Director
--
--
Mr. Grady Grant, III
Mr. Grady Grant, III
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Marvin L. White
Mr. Marvin L. White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
43.00
+30.30%
Mr. Jeffrey G. Lamothe
Mr. Jeffrey G. Lamothe
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
23.00
+27.78%
Ms. Barbara Lopez Kunz
Ms. Barbara Lopez Kunz
Independent Director
Independent Director
1.00
--
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Director
Independent Director
1.00
--
Dr. John E. Niederhuber, M.D.
Dr. John E. Niederhuber, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.00
--
Ms. So Young Kwon
Ms. So Young Kwon
Senior Vice President, General Counsel, Business Development and Corporate Affairs
Senior Vice President, General Counsel, Business Development and Corporate Affairs
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 23
Updated: Wed, Jul 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Schiketanz Capital Advisors GmbH
0.02%
Geode Capital Management, L.L.C.
0.02%
Other
99.96%
Shareholders
Shareholders
Proportion
Schiketanz Capital Advisors GmbH
0.02%
Geode Capital Management, L.L.C.
0.02%
Other
99.96%
Shareholder Types
Shareholders
Proportion
Investment Advisor
0.02%
Investment Advisor/Hedge Fund
0.02%
Research Firm
0.01%
Other
99.95%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
37
1.61K
0.06%
-24.39K
2025Q1
50
1.38K
0.06%
-4.41K
2024Q4
49
48.74K
3.37%
-20.87K
2024Q3
46
34.83K
7.56%
-18.81K
2024Q2
48
53.21K
48.29%
+52.02K
2024Q1
49
188.00
1.03%
-1.27K
2023Q4
51
1.27K
10.69%
-1.06K
2023Q3
56
2.18K
24.99%
+1.07K
2023Q2
60
629.00
13.58%
-1.76K
2023Q1
67
602.00
13.71%
-1.90K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Schiketanz Capital Advisors GmbH
290.00
0.01%
+290.00
--
Jan 31, 2025
Geode Capital Management, L.L.C.
526.00
0.02%
+526.00
--
Mar 31, 2025
Tower Research Capital LLC
163.00
0.01%
+109.00
+201.85%
Mar 31, 2025
Clear Street LLC
140.00
0%
+140.00
--
Mar 31, 2025
BofA Global Research (US)
116.00
0%
+116.00
--
Mar 31, 2025
White (Marvin L)
3.00
0%
+1.00
+50.00%
Apr 04, 2025
SBI Securities Co., Ltd.
35.00
0%
+28.00
+400.00%
Mar 31, 2025
Lamothe (Jeffrey G)
2.00
0%
--
--
Apr 04, 2025
Kwon (SoYoung)
1.00
0%
--
--
Apr 04, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Mar 04, 2024
Merger
44<1
Mar 04, 2024
Merger
44<1
Date
Type
Ratio
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Mar 04, 2024
Merger
44<1
Mar 04, 2024
Merger
44<1
Mar 04, 2024
Merger
44<1
Mar 04, 2024
Merger
44<1
Mar 26, 2020
Merger
14<1
Mar 26, 2020
Merger
14<1
View more
